Proactive investorsLogo Proactive Investors UK Website

Search field
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
Epic: VALRF
News: Latest news
Web Site: ValiRx plc
Other Articles: 25-11-200929-07-200905-05-2009

ValiRx plc

ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.

Wednesday, November 25, 2009

ValiRx reports encouraging initial sales at ValiMedix, expects global agreements for diagnostics products

company news image

ValiRx (AIM: VAL) today announced encouraging initial sales at its newly established diagnostic kits business ValiMedix, while the development of the HPV infection test by its joint venture (JV) with bio.be ValiBio has been progressed to meet recent FDA (Food and Drug Administration) guidelines with a prototype test currently undergoing analytical validation.


Other developments at ValiBio included the development of a prototype nucleosome test with discussions to use some of the antibodies for the test currently ongoing. In addition, the company has taken over a clinically proven histone biomarker for lung cancer prognosis, enabling an immunohistochemical tissue biopsy test and a Nucleosomics blood test to enter development for lung cancer prognosis.


The first sales across the whole range in ValiMedix’ first six weeks of trading was a major step in its transition from a pre-revenue biotech company to a commercial life sciences business, ValiRx said in the statement. ValiMedix is in discussions to extend its brand portfolio and aims to roll out additional diagnostic kits in its markets, also expecting to add global agreements for its diagnostic products with key partners to its existing UK distribution contracts.


ValiRx is currently looking for ways to raise additional capital to develop its operations, being dependant on its ability to secure grants and raise funds through the issue of further equity. The company confirmed it was in discussions with Biofield Corp over the payment of €600,000 with additional compensation of €60,000 due to ValiRx after the disposal of 10% of its holdings in its subsidiary ValiBio S.A. The payment of the consideration has been extended to 31 December this year.


Shares in the company rallied 21% on the news.

NewsNow icon AddThis Feed Button
Register here to be notified of future ValiRx plc articles.

Other ValiRx plc news

More news ►

Investors interested in ValiRx plc recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.